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Introduction 
The present study was undertaken to compare in a cross-over design in both 
males and females, the bioavaiIability of rifampicin, when given in a 
combined formulation with isoniazid, between an established standard 
product and a locally produced generic product. 
Methodology 
The study was performed on 12 healthy male volunteers with a mean age 
of 23 yrs (range 22-24 yrs ) and a mean body weight of 75 Kgs ( range 60-90 
Kgs ) and on12 healthy female volunteers with a mean age of 22 yrs ( range 
20-26 yrs ) and a mean body weight of 54 Kgs ( range 45-63 Kgs). Each 
volunteer had no contraindication tb rifampicin administration and none of 
the subjects was on any other medication for the last 15 days prior to the 
study or during the study. A cross-over design was adopted with a washout 
period of one week between the two treatments. The study was performed 
after a single dose of 600mg rifampicin 300mg isoniazid combination ( adult 
dose) of the two formulations [ Rimactazid®( batch no. 02330)- Ciba-Geigy ; 
Rifampicin & Isoniazid Tablets (batch no. 0011) - Pharmamed J. The single 
oral dose of the combined formulation was administered to each subject with 
200mls of water on an empty stomach. The study was carried out using two 
different means of sample c~llection: 
A. Saliva Sampling B. Urine Sampling 
A.Saliva Sampling 
The observations that salivary drug concentration is often ~roportional to 
plasma drug concehtration led to the use of saliva as a non invasive technique. 
for obtaining pharmacokinetic data. 
Measurement of drug concentration in saliva offers several advantages over 
Similar measurements performed in plasma. In the first place, many speci-
mens can be obtained noninvasively, without loss of blood or exposure to 
discomfol't and potential skin irritation and hazards of infection as with 
repeated venepunctures. Secondly it does not require attendance of medical 
staff, but more importantly, is the fact that the drug concentration in saliva 
represents the free fraction of drug, whereas data on concentration in plasma 
represents both the free and protein bound forms of the drug. Only free forms 
of the drug can produce a pharmacological response, so measurements of 
drug concentration in saliva are more therapeutically meaningful ( Dvorchik 
et ai, 1976; Paxton, 1979 ) 
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B.Urine Sampling 
Urine sampling was used to monitor the cumulative amount of drug which 
was excreted in the urine. This aspect was then analyzed using cumulative 
urinary excretion data and applying this pharmacokinetic principle in 
estimating the difference, if any, between the two products in both males and 
females. 
Analysis of Salivary Drug Concentrations 
Saliva samples were collected in sterile containers at 0,1,2,4,6,8, 12 and 24 
hours after drug administration. All samples were processed immediately 
after collection. Rifampicin concentrations were determined by the plate 
diffusion assay employing a strain of 5 taphylococcus aureus (subgroup 1, NCTC 
10702) resistant to streptomycin and antibiotics (including isoniazid) other 
than rifampicin ( Gurumurthy et ai, 1990). Rifampicin standards ranging 
from 0.15 to 600 Ilg/ml were set up in quadruplicate and the concentrations 
of the drug in saliva samples were obtained from the regression line of the 
diameter of the zone of inhibition on log concentration of the standard. 
Calculation of Pharmacokinetic Variables 
The peak concentration ( Crnax )was the geometric mean of the highest 
concentration in individual volunteers. The time to reach the peak 
concentration ( T rnax ) was the mean of the values obtained for each 
individual. Exposure was calculated as the area under the concentra tion-time 
curve ( AUC ). 
Analysis of Urinary Drug Concentrations 
Since relatively large amounts of :unchanged rifampicin are excreted in urine 
and since it has been shown thatthe AUCunder the plasma concentration plot 
is directly proportional to the amount excreted in urine during the same time 
interval, the bioavailability of rifampicin from oral dosage forms may be 
assessed more conveniently by measuring the urinl\ry elimination 
spectrophotometrically ( Brechbiihler et ai, 1978 ). 
Urine was collected at 0, 1. 2, 4, 6, 8, 12, 24, 28, 30 and 32 hours after 
administration of the adult dose as discussed earlier. The volunteers emptied 
their bladders immediately before swallowing the doses ( at time 0 ) and all 
urine samples were collected and their volumes were also noted. The 
rifampicin concentration and consequently the amount of drug excreted was 
determined bv the method adopted by Brechbiihler et aI, ( 1978). 
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In brief this method involved the extraction of rifampicin from the urine into 
toluene and then measuring the optical density of 'the extract 
spectophotometrically at 478nrn and correlating the rifampicin concentration 
by means of calibration curves. The toluene extract of urine from volunteers 
contained not only unchanged rifampicin but also the metabolite 25-
desacetylrifampicin, and since this shows the same absorption spectrum as 
'rifampicin, it could not be differentiated from rifampicin ( Brechbiihler et ai, 
1978). The spectroscopically determined sum of rifampicin and desacetyl 
metabOlite was referred to as apparent rifampicin. 
Rifampicin in urine was almost completely extracted by using a mixture 
solvent consisting of an equal volume of benzene and hexane, since extraction 
of desacetylrifarnpicin in the solvent is negligible (Sunahara et ai, 1972). On 
this principle, the urine sample which was treated with the benzene-hexane 
mixture, was re-extracted with tne previ,ous method and the absorption 
maximum wa~ obtained for the metabolites. 
The concentration of unchanged rifampicin in the urine sample was calculated 
as the difference in value between the toluene extracts containing the apparen t 
rifampicin and the toluene extract containing the metabolite. 
Results 
The results were expressed as mean ±SEM and an analy'sis of variance 
(ANOV A), employing tM PC-90 version of BMDP for IBM computers and 
compatables, was applied for statistical purpose. P< 0.05 was considered 
statistically significant. 
A. Saliva 
Table 1 & 2 show the mean salivary rifampicin levels at different time 
. intervals after the single oral dose of 600mg of both Treatment A ( Standard 
drug manufactured by Ciba-Geigy ) and Treatment B ( Test drug 
manufactured by Pharmamed ) was administered to male and female 
volunteers respectively. 
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0.000 0.000 0.000 0.000 O.OCO O.OCO O.OCO O.OCO 
0.019 0.0711 0.165 0.1IIl8 0.203 0.122 0.264 0.169 
1.6'lS 0.905 0.259 0.102 0.6(6 0.263 0.346 0.127 
0222 0.085 0.11111 O.lll 0.482 0.196 0.368 0.132 
o.m 0.015 0.163 0.!8! O.))} 0.136 0.216 OJJ90 
0.076 0.045 0.019 0.108 0.154 0.070 0.116 0.061 
II 0.026 0.0211 O.D1S 0.020 II 0.041 0.02!I 0.029 0.02!I 
24 0.001 0.000 0.001 0.000 24 0.003 O.OCO 0.001 O.OCO 
Table 1. Mean Salivary Rifampicin Table 2. Mean Salivary Rifampicin 
Levels at different time intervals Levels at different time intervals 
after the oral dose of Treatments A after the oral dose of Treatments A 
& B in male volunteers. & B in female volunteers. 
The graphical representations showing the mean salivary rifampicin 
concentrations obtained at different time intervals in male and female vol-
unteers, are given in Figures 1 & 2 respectively. 
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Figure 1. Mean Salivary Rifampicin 
Levels at different time intervals 
after the oral dose of Treatments A 
& B in 12 male volunteers. 
644 
:)5:) 
Variation of Salivary Rifampicin Concentration 
velSus time for Trealmenls A and B 
-+- TrellllllllA 
... :: ... T!!IImenIB 
Time (hrs) 
Figure 2. Mean Salivary Rifampicin 
Levels at different time intervals 
after the oral dose of Treatments A 
& B in 12 female volunteers. 
Table 3 & 4 give the mean ± SEM for the three pharmacokinetic parameters 
which were considered, ie. Cmax, Tmax , and AUC, as observed in the male 
and female volunteers respectively. 
AF 0.800 3.799 1.0S7 7.493 
AA O.19~ 2 0.752 0.219 1.062 
AS 0.175 4 0.705 0.084 0.563 
CS 0.201 4 1.659 0.537 2.298 
HA 0.120 0.839 O.20~ 0.847 
Table 3. IM 0.093 4 0.536 0.138 0.716 
The means of the the IM 0.594 1.477 0.195 1.832 
three pharmacokinetic IM 1.153 4.838 0.433 2 1.2S1 
MM 0.261 4 1.187 D.253 0.687 parameters investi- WB 0.253 1.069 0.439 1.626 
gated following the oral CF 0.142 4 0,903 0.178 0.682 
administration of ss 0.313 2 2.654 0.140 1.037 
Treatments A & B in 
male volunteers. 
AB 0.923 4.769 0.592 4 3.805 
AM 0.622 2.543 0..252 2 1.260 
CC 0.378 1.742 0.223 1.117 
cz 0.783 3.145 0.526 2.694 
CM 0.439 2.550 0.560 4 3.592 
EA 0.276 1.451 0.291 1.B05 Table 4. 
HO 0.458 1.956 0.172 4 1.023 The means of the the 
MP 1.322 2 5.756 0.576 4 2.277 
MS 1.098 4.301 0.691 2 2.509 three pharmacokinetic 
NP 1.294 7.532 0.761 4 5.008 parameters investi-
MP 0.519 4 2.937 0.626 3.174 gated following the oral 
MM 0.698 3..282 0.828 2.291 
administration of 
Treatments A & B in 
female volunteers. 
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On comparing the mean values for every pharmacokinetic 
parameter in Treatments A and B it was noted that the means for Treatment 
B were slightly lower than those for Treatment A. However, no statistically 
significant difference in the calculated mean ( ± SEM ) value of the 
pharmacokinetic parameters Cmax, T max' and AUC for both male and female 
volunteers could be detected between the two treatments. 
B. Urine 
Tables 5 & 6 show the amount of drug excreted at infinite time, AeOQ for both 
treatments in male and female volunteers respectively. 
0.000 0.000 0.000 0.000 
2.594 2.980 1.830 0.756 
9.430 3.319 8.361 2.527 
22.535 3.768 20.887 3.978 
33.384 4.707 29.337 5.986 
44.164 5.179 37.043 6.196 Table 5. The mean amounts 
12 52.358 7.785 45.6.54 7.351 of drug excreted unchanged 
24 60.715 10.453 SO.SOl 9.024 at different time intervals 
28 60.915 10.453 51.128 9.032 after the oral adminis tration 
30 60.915 10.453 51.128 9.232 of Treatments A & B in 
32 60.915 10.453 51.128 9.032 
male volunteers. 
0.000 0.000 0.000 0.000 
0.539 1.531 1.429 1.226 
5.919 2.177 6.081 3.201 
20.997 3.630 17.832 4.902 
34.987 4.751 30.995 5.303 
Table 6. The mean amounts 49.146 6.488 41.106 7.388 
of drug excreted unchanged 12 59.739 8.831 48.024 8.058 
at different time intervals 24 71.596 10.233 55.350 10.140 
after the oral administration 28 72.405 10.242 55.654 10.130 
of Treatmenfs A & B in 30 72.405 10.242 55.654 10.130 
female volunteers. 32 72.405 10.242 55.654 10.130 
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Table 7 shows the amount of drug excreted at infinite time, Aeoo for both 
treatments in male and female volunteers respectively. 
AA. ~S.9'16 27.4'17 .Al\.1: 39.293 49.506 
AS 58.044 47.001 cc: 75.063 49.3cx) 
cs 63.767 60.844 CZ 66.741. 38.876 
~ 34.854- 44.682 c::I'<[ 85.891 89.429 
""'" 
72.972 75.097 HA 75.695 44.585 
""'" 
28.1.78 43.366 rn:> 82.753 71..3'19 
llv.[ 7'1.286 40.91.6 "-U> 82.786 30.931. 
~ 54.368 41..291. "",. 54 . .536 46.546 
VVB 58.670 47.21.1. NI> 83.274- 69 . .547 
CF 74.814 67.689 "-U> 50.931. 59.208 
Table 7. The mean amounts of drug excreted unchanged at infinite 
time Aeoo for Treatments A & B in both male and female volunteers. 
Figures3 & 4 show a graphical representation of the mean cumulative urinary 
excretion of unchanged drug for both treatments in male and female 
volunteers respectively. 
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Both means for the test drug were lower than the corresponding means for the 
standard drug in both males and females. There was no statistically 
significant difference between the means of drug excreted unchanged after 
Treatment A and Treatment B in males. However, this difference was 
statistically significant in females. 
Conclusion 
The present study was undertaken to compare the oral bioavailability of 
rifampicin from a new combined formulation with that of a widely prescribed 
brand. 
The results obtained document the comparable bioavailability of both drug 
formulations. However, there is an indication of some variation between 
the results obtained in males and female. This imparts a reduced clari ty abou t 
the precise significance of classical bioequivalence testing, which is carried 
out on healthy young male subjects only, since such studies may not 
represent the action of the drug in the whole population. 
The results also showed that in all the parameters measured, the test drug 
results were slightly lower than those for the standard drug. This can be 
attributed to the characteristics of solid state and physical properties of the 
rifampicin molecule, which have been-studied extensively to ascertain their 
influence on the bioavailability of the drug. Rifampicin has been shown to 
exist in two polymorphic forms as a single entity, in several solvates and in an 
amorphous phase. Its crystalline habitCan be changed as a consequence of the 
manufacturing procedure used in the preparation of the dosage form. 
In studies carried out oy Cavenaghi, the results showed that variations in 
particle size, excipients or manufacturing process may result in a marked 
decrease in the absorption of rifampicin ( Cavenaghi, 1989). Therefore, 
modifications in the pharmaceutical properties andmanufacture process of 
the generic drug may be necessary in order to approach even more the 
bioavailability profile of the standard product. 
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